To find investment opportunities, don't try to cover an entire industry. Instead, concentrate capital and research where change is happening most quickly and dramatically. This is where incumbents are most vulnerable and new value is created, as disruption equals opportunity.

Established industries often operate like cartels with unwritten rules, such as avoiding aggressive marketing. New entrants gain a significant edge by deliberately violating these norms, forcing incumbents to react to a game they don't want to play. This creates differentiation beyond the core product or service.

Truly transformative healthcare companies often solve "boring" but fundamental problems. Instead of tackling surface-level symptoms (e.g., appointment booking), the best founders dig deep to fix the complex, underlying infrastructure issues of the healthcare system, creating a durable competitive moat.

GC believes technology's natural gravity pulls toward concentration in a few mega-companies. Its investment thesis is to empower founders to build power-law companies that create a more distributed and inclusive innovation ecosystem, actively working against this concentration.

Big Pharma operates less like a traditional manufacturer and more like a venture capital firm, managing a portfolio of high-risk assets (drug targets) and allocating capital accordingly. This mental model explains their focus on platform technologies that improve the success rate of their portfolio bets.

Draper deliberately avoids mainstream, crowded markets. He prefers ideas that are "around the edges" and controversial because they face less competition. This contrarian strategy is designed to find companies with the potential for massive, world-changing impact if they succeed.

Companies like Amazon (from books to cloud) and Intuitive Surgical (from one specific surgery to many) became massive winners by creating new markets, not just conquering existing ones. Investors should prioritize businesses with the innovative capacity to expand their TAM, as initial market sizes are often misleadingly small.

When evaluating revolutionary ideas, traditional Total Addressable Market (TAM) analysis is useless. VCs should instead bet on founders with a "world-bending vision" capable of inducing a new market, not just capturing an existing one. Have the humility to admit you can't predict market size and instead back the visionary founder.

Ken Griffin warns startups against direct, head-on competition with industry giants, stating, "you're going to lose." To succeed, you must find an asymmetrical advantage—operating "under the radar" or solving niche problems incumbents ignore. Citadel initially did this by hiring unconventional quantitative talent.